Search
Search Results
##search.searchResults.foundPlural##
-
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3669PDF: 1703HTML: 5986Fig1-Ag-Pil: 289Ag-Pil Fig.2: 288 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3768PDF: 1316HTML: 532 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
3107PDF: 1196HTML: 137 -
IMMUNOLOGICAL EVOLUTION OF A COHORT OF HIV-2 INFECTED PATIENTS: PECULIARITIES OF AN UNDERESTIMATED INFECTION HIV-2 INFECTED PATIENTS PECULIARITIES
1148PDF: 712HTML: 282 -
EARLY PREDICTIVE VALUE OF PERIPHERAL INFLAMMATORY INDEX COMBINED WITH HIGH-SENSITIVITY TROPONIN T FOR SEPSIS-INDUCED CARDIOMYOPATHY Inflammatory and Troponin T in cardiomyopathy from Sepsis
445PDF: 437HTML: 237 -
-
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4806PDF: 3959HTML: 383 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2364PDF: 1069HTML: 1996 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
2180PDF: 982HTML: 1115 -
AN INEXPENSIVE CLINICAL-LABORATORY NOMOGRAM TO PREDICT POST-TREATMENT LUNG DESTRUCTION IN PULMONARY TUBERCULOSIS
782PDF: 396Suppl. Files: 100Html: 86 -
Pathogen distribution, antimicrobial resistance, and mortality in febrile neutropenia among adults with hematological malignancies: a single-center cohort study
91PDF: 37Suppl. Files: 11Html: 25Html Suppl. Files: 6 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
2139PDF: 899HTML: 270 -
ANORECTAL PATHOLOGIES IN THE COURSE OF ACUTE LEUKAEMIAS: PREDICTIVE PARAMETERS Anorectal pathologies in leukemias
1335PDF: 826Html: 130 -
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1321PDF: 656HTML: 6942 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2721PDF: 922HTML: 9076Efremov 1: 278Efremov 2: 247 -
-
FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator
3224PDF: 1115HTML: 3373 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1693PDF: 1111HTML: 151 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4163PDF: 1139HTML: 3919Untitled: 205Cneo. Fig.1: 147Untitled: 138Untitled: 173Untitled: 175 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1576PDF: 904HTML: 3151 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3972PDF: 1720HTML: 889Figures . Eliassian: 325 -
HEMATOLOGICAL ABNORMALITIES BEYOND LYMPHOCYTOSIS DURING INFECTIOUS MONONUCLEOSIS: EPSTEIN-BARR VIRUS-INDUCED THROMBOCYTOPENIA THROMBOCYTOPENIA DURING INFECTIOUS MONONUCLEOSIS
2532HTML: 692PDF: 1451 -
BONE MARROW ABONRMALITIES IN HIV INFECTION
2053PDF: 1224HTML: 1800 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1540PDF: 877HTML: 1042 -
CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
3492PDF: 990HTML: 1561Fig.1 CHL-R paper: 268Fig 2 CHL-R paper: 309 -
Severe autoimmune hemolytic anemia in Covid-19 infection Autoimmune hemolytic anemia in Covid-19
3516PDF: 1693HTML: 297 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4730PDF: 1833HTML: 1387 -







